文献类型：期刊文献

英文题名：Survival benefit of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after anatomical hepatectomy

作者：Ye, Tai-Wei[1,2];Wang, Dong-Dong[1];Lu, Wen-Feng[3];Xie, Ya-Ming[1];Xu, Fei-Qi[1];Fu, Tian-Wei[1];Zhang, Kang-Jun[1];Liu, Si-Yu[4];Xie, Gui-Lin[5];Cheng, Jian[1];Jiang, Kai[1];Xiao, Zun-Qiang[1];Yao, Wei-Feng[1];Shen, Guo-Liang[1];Liu, Jun-Wei[1];Huang, Dong-Sheng[1,6,7];Zhang, Cheng-Wu[1,8];Liang, Lei[1,6,8]

机构：[1]Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Hangzhou Med Coll, Gen Surg Canc Ctr,Dept Hepatobiliary & Pancreat Su, Hangzhou, Zhejiang, Peoples R China;[2]Zhejiang Chinese Med Univ, Sch Clin Med 2, Hangzhou, Zhejiang, Peoples R China;[3]Navy Med Univ, Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepatobiliary Surg, Zhejiang, Peoples R China;[4]Shaoxing Univ, Affiliated Hosp, Lishui Municipal Cent Hosp, Dept Med, Shaoxing, Zhejiang, Peoples R China;[5]Shaoxing Univ, Affiliated Hosp, Dept Hepatobiliary Surg, Shaoxing, Zhejiang, Peoples R China;[6]Key Lab Tumor Mol Diag & Individualized Med Zhejia, Hangzhou, Zhejiang, Peoples R China;[7]Hangzhou Med Coll, Dept Clin Med, Hangzhou, Zhejiang, Peoples R China;[8]Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Hangzhou Med Coll, Gen Surg Canc Ctr,Dept Hepatobiliary & Pancreat Su, Hangzhou 310014, Zhejiang, Peoples R China

年份：2023

卷号：17

期号：4

起止页码：395

外文期刊名：EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY

收录：SCI-EXPANDED(收录号：WOS:000950904000001)、、Scopus(收录号：2-s2.0-85150891973)、WOS

基金：This paper was funded by Health Commission of Zhejiang Province (No.2022KY532) and Zhejiang Provincial People's Hospital (No. ZRY2020A004).

语种：英文

外文关键词：Hepatocellular carcinoma; hepatectomy; transcatheter arterial chemoembolization; adjuvant therapy; survival

外文摘要：Background & aimsAlthough anatomical hepatectomy (AH) is widely used in the treatment of hepatocellular carcinoma (HCC), the prognosis is still unsatisfactory. The present study aimed to evaluate the survival benefit of adjuvant transcatheter arterial chemoembolization (TACE) for patients with HCC after AH.MethodsA total of 832 patients were stratified into with adjuvant TACE (443, 53.2%) and without adjuvant TACE group (389, 46.8%) AH. Propensity score matching (PSM) was performed to control for confounding factors, and multivariable Cox regression was performed to determine the independent risk factors.ResultsAfter PSM, the results showed that the adjuvant TACE group had better overall survival (OS) and recurrence-free survival (RFS). Among the patients with tumor recurrence, adjuvant TACE was associated with a high rate of early-stage tumor at recurrence, a lower recurrence rate around the frontal margin and extrahepatic metastases, and a higher rate of receiving curative treatment. Multivariable Cox regression analysis showed that adjuvant TACE was an independent prognostic factor for OS (HR 0.673, P = 0.001) and RFS (HR 0.650, P = 0.001).ConclusionsPatients with HCC after AH can benefit from postoperative adjuvant TACE. Therefore, adjuvant TACE should be considered for patients with a high risk of recurrence.